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INTRODUCTION
Acute graft-versus-host disease (aGVHD) remains a
major cause of serious morbidity and mortality after allo-
geneic bone marrow transplantation (BMT). Overall, less
than 50% of patients with aGVHD show durable
improvement after initial treatment. Therapy with gluco-
corticoids for aGVHD is suboptimal, with continuing
complete response in 41% of histocompatible-sibling allo-
geneic transplant recipients [1]. Response in unrelated
donor (URD)-transplant recipients is even more disap-
pointing, with only 24% of patients showing improvement
after therapy with corticosteroids [2]. Salvage treatment is
often required for patients who fail to achieve an adequate
response to steroids. Mortality is particularly high in this
group of patients with steroid-refractory GVHD [3].
Antithymocyte globulin (ATG) is frequently included in
secondary therapy. Improvement or disease stabilization
has been seen in up to 56% of patients receiving ATG as
second-line therapy [3,4]. Even in URD-transplant recipi-
ents, secondary therapy with ATG has led to improvement
in 4 (19%) of 21 patients [2]. Retrospective analyses from
Seattle [3] and Minnesota [4] studies of steroid-refractory
aGVHD response rates to secondary treatment with ATG,
assessed at 28 to 29 days posttherapy, showed complete
plus partial responses (CR + PR) in the range of 30% to
68%. Six-month survival of patients receiving secondary
ATG was reported by the Minnesota study to be 40% [4].
In the randomized trial by Cragg et al. [5], ATG/pred-
nisone as initial therapy failed to control aGVHD or
improve survival, compared to prednisone alone, for
patients with moderately severe aGVHD. However, this
trial also examined second-line therapy that consisted of
ATG/prednisone and reported successful results for the
combination when prednisone alone had failed. These
results helped to support ATG/prednisone as a considera-
tion for second-line therapy in the management of
aGVHD. Still, the data on the efficacy of ATG therapy
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ABSTRACT
Treatment of acute graft-versus-host disease (aGVHD) has relied on high-dose steroids, but less than 50% of
patients show durable remission. Antithymocyte globulin (ATG) has become a standard salvage therapy. We now
report our experience with ATG for the treatment of steroid-refractory GVHD in 69 patients treated from January 1,
1980, to May 1, 1999. Patients with GVHD were given an overall grade using standard criteria. Overall responses
were similar to those in previously published literature. However, long-term survival for this group of patients was
dismal. Of the 69 patients treated with ATG for steroid-refractory GVHD, only 3 (5%) are currently alive. The
median survival of these patients by GVHD grade was 4.1 months for grade 2, 3.6 months for grade 3, and
2.7 months for grade 4. The age range of the surviving patients was 3 to 25 years. Only 5% of the deaths were due
to relapse, with the remaining deaths due to GVHD, infection, and/or organ failure. In conclusion, ATG treatment
can produce objective responses in patients with aGVHD, but these responses do not result in long-term survival.
Given the poor survival rates of patients treated with ATG for steroid-refractory GVHD, treatment with ATG as
standard therapy should be reconsidered. Patients with steroid-refractory GVHD should be enrolled in clinical
study until there are data to support a standard salvage therapy.
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for patients with steroid-refractory GVHD remain in
question because of other studies reporting poor out-
comes [6-11].
We report our experience with ATG for the treatment
of steroid-refractory aGVHD, with the objective of deﬁning
both the response rate to second-line ATG-plus-steroid
therapy and the impact of such therapy on patient survival.
We retrospectively analyzed the outcome of ATG therapy in
69 patients with steroid-refractory aGVHD.
MATERIALS AND METHODS
Patients
Records were reviewed for all patients given ATG sal-
vage therapy for steroid-refractory aGVHD after allogeneic
marrow transplantation at Johns Hopkins Hospital between
January 1, 1980, and May 1, 1999. Sixty-nine patients
received ATG salvage therapy for steroid-refractory
aGVHD. Steroid refractoriness was defined as
persistent/progressive aGVHD despite administration of
corticosteroids or a ﬂare of GVHD on steroid tapering that
responded incompletely to reinstitution of higher steroid
doses, including pulse-dose steroids.
GVHD stage and grade were recorded at the initiation
of ATG therapy using the modiﬁed Keystone criteria [12].
Because this was a retrospective study spanning 19 years,
there was discrepancy in our own internal grading of
GVHD between early and later patients who were graded
according to standard criteria. Speciﬁcally, early patients had
to have elevations of both bilirubin and liver enzymes to be
considered as having organ GVHD. To standardize report-
ing, the most recent modified Keystone criteria [12] was
applied to all patients.
The severity of skin disease was staged according to the
extent of skin surface area involvement: stage 1, <25%; stage
2, 25% to 50%; stage 3, >50%; and stage 4, generalized ery-
throderma with bullous formation. Severity of hepatic dys-
function was staged according to serum bilirubin concentra-
tion: stage 1, 2.0 to 3.0 mg/dL; stage 2, 3.1 to 6.0 mg/dL;
stage 3, 6.1 to 15 mg/dL; and stage 4, >15 mg/dL. Severity
of gut dysfunction was staged according to volume of diar-
rhea and presence of persistent nausea or abdominal pain:
stage 1, diarrhea volume ≥500 mL/day or persistent nausea;
stage 2, diarrhea volume ≥1000 mL/day; stage 3, diarrhea
volume ≥1500 mL/day; and stage 4, severe abdominal pain
with or without ileus.
Overall clinical grade 1 was deﬁned as limited stage 1-2
skin involvement, with no liver or gut involvement. Grade 1
was considered mild aGVHD, not requiring systemic treat-
ment. Clinical grade 2 was defined as stage 3 skin rash or
stage 1 liver or gut involvement. Clinical grade 3 was deﬁned
as skin rash ranging from none to stage 3 along with stage 2-
3 liver or stage 2-4 gut involvement. Clinical grade 4 was
defined as stage 4 skin rash, or stage 4 liver involvement.
Clinical grades 2 through 4 were considered moderate to
severe aGVHD, requiring systemic treatment intervention.
Treatment
Primary therapy for aGVHD consisted of cyclosporine
and initiation of methylprednisolone (median dosage, 2
mg/kg per day; range, 0.5-10 mg/kg per day). This therapy
was started when patients developed clinical evidence of
aGVHD. Salvage therapy with ATG was initiated when it
was determined by the attending physician and GVHD
team that the response to primary therapy was less than sat-
isfactory. In general, ATG salvage therapy was started in
patients if aGVHD was persistent/progressive despite
administration of corticosteroids (median dosage, 2 mg/kg
per day) or if there was a ﬂare of GVHD on steroid tapering
that responded incompletely to reinstitution of higher
steroid dosages (up to 2.5 mg/kg per day), including pulse
steroid dosages (10 mg/kg per day). ATG was administered
at dosages of 10 to 15 mg/kg every other day for 7 doses,
followed by a second course if there was a response.
Cyclosporin A (CSA) alone, CSA plus methotrexate (MTX),
MTX alone, elutriation plus CSA, and CSA plus steroid
were the regimens administered for GVHD prophylaxis
(Table 1). CSA dose was 5 mg/kg intravenously (IV) with
dose adjusted to maintain a whole blood level above 200
ng/mL thereafter. CSA and tapering steroids were contin-
ued during ATG therapy unless there was toxicity preclud-
ing their use.
Table 1. Patient Characteristics*
n (%)
Total no. of patients 69 (100)
Age: 1-51 y (median, 30.5 y)
≤35 y 41
>35 y 25
Sex
Male 51 (74)
Female 18 (26)
Diagnosis
AML 17 (25)
ALL 10 (14)
CML 28 (41)
Hodgkin’s lymphoma 3 (4)
NHL 3 (4)
Aplastic anemia 2 (3)
Other† 6 (9)
Transplant type
Matched related 59 (86)
Matched unrelated 7 (10)
Mismatched related 3 (4)
Conditioning regimen
BuCyThio 1 (1)
BuCy 28 (41)
CyTBI 27 (39)
BuVP16Cy 9 (13)
Other‡ 4 (6)
GVHD prophylaxis
CSA 50 (72)
CSAMTX 1 (1)
MTX 1 (1)
Other§ 17 (25)
*AML indicates acute myelogenous leukemia; ALL, acute lympho-
cytic leukemia; CML, chronic myelogenous leukemia; NHL, non-
Hodgkin’s lymphoma; BuCyThio, busulfan, cyclophosphamide,
thiotepa; VP16, etoposide.
†Includes multiple myeloma and myelodysplastic syndrome.
‡Includes CyCSA and donor lymphocyte infusion.
§Includes elutriation (E), ECSA, steroid CSA, and Cy.
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Measurements of Response
Response to ATG salvage therapy in each organ
involved was evaluated weekly until complete response or
death. An overall response was also determined for each
patient. Responses were defined as follows: complete
response (CR), resolution of all symptoms attributed to
GVHD; partial response (PR), improvement in 1 or more
organ system without deterioration in others; mixed
response (MR), improvement in 1 or more organ system
with deterioration in others; progressive, deterioration in
1 or more organ system without improvement in others; and
no response, no change in any organ system.
Statistical Analysis
The primary statistical outcome of this study was sur-
vival in patients with steroid-refractory aGVHD who
received ATG treatment. Event-time distributions for the
survival endpoints were estimated with the Kaplan-Meier
method [13] and compared using the log-rank statistic [14]
or the proportional hazards regression model [15]. The
simultaneous effect of 2 or more factors was studied using
the multivariate proportional hazards model. Covariates
marginally significant in univariate analyses were entered
into the multivariate regression model and nonsignificant
effects were removed in a stepwise fashion. Variables
included as potential risk factors were age, sex, diagnosis,
conditioning regimen, type of GVHD prophylaxis, type of
BMT, maximum grade of GVHD at time of ATG treat-
ment, progressive or no response to ATG versus CR/PR to
ATG by organ involvement, steroid dose pre–ATG treat-
ment, steroid dose post–ATG treatment, total steroid dose,
and total days on steroids prior to ATG treatment.
All P values are 2-sided. Computations were performed
using the Statistical Analysis System [16] or EGRET [17].
RESULTS
Patient Characteristics 
From January 1, 1980, to May 1, 1999, 69 allogeneic
marrow–transplant recipients were given salvage therapy for
steroid-refractory aGVHD. Demographic characteristics of
the patients are listed in Table 1.
At the onset of aGVHD, primary treatment was initi-
ated with methylprednisolone at a median dosage of 2
mg/kg per day (range, 0.5-10 mg/kg per day). In many
cases, the steroid dose was increased after an initial taper, in
response to GVHD recurrence, constituting a second
steroid course (up to 2.5 mg/kg per day) prior to salvage
ATG therapy. Salvage treatment with ATG (10-15 mg/kg
every other day for 7 doses) was initiated at a median of 46
days after transplantation, with a median 24.5-day interval
between primary and ATG salvage treatments. GVHD was
confirmed by biopsy of the respective organ in all cases.
Skin GVHD was diagnosed in 81% of patients; liver
GVHD was diagnosed in 78% of patients; and gastrointesti-
nal (GI) GVHD was diagnosed in 59% of patients. Four-
teen percent of patients had skin-only involvement; 12%
had liver-only involvement; but the majority, 74%, had mul-
tiorgan/system GVHD, deﬁned as involvement of 2 or more
organs.
Organ dysfunction other than GVHD was ruled out
with biopsy.
Organ Response to Salvage Treatment With ATG
Improvement or resolution of GVHD in the respective
organ (CR + PR) was seen in 59% of patients with skin dis-
ease, 15% of patients with liver disease, and 32% of patients
with gut disease (Table 2). No change in GVHD was seen in
32% of patients with skin disease, 52% of patients with liver
disease, and 32% of patients with gut disease. Progression of
involvement was seen in 9% of patients with skin disease,
33% of patients with liver disease, and 37% of patients with
gut disease. Progression was more likely in liver and gut dis-
ease than in skin disease.
Overall Response After Salvage Treatment With ATG 
For each patient, an overall response was determined
according to the outcome in each organ involved. We then
analyzed overall response to ATG therapy by the maximum
grade (2-4) of aGVHD (Table 3). Forty-one percent (11/27)
of maximum grade 2–GVHD patients achieved overall
improvement (CR + PR) with ATG salvage therapy, and
24% (10/42) of severe grade 3-4–GVHD patients showed
overall improvement (CR + PR). Looking at responses of
patients in all grades of aGVHD treated with ATG, we
found that 14% of patients had a complete response, 30%
showed overall improvement (CR + PR), and 56% showed
improvement in at least 1 organ (CR + PR + MR). These
results are similar to those previously reported for secondary
treatment of aGVHD [3].
Long-term Survival Following ATG Therapy 
Median survival was assessed for all patients with
steroid-refractory GVHD by maximum GVHD grade
(Table 4). These results show dismal survival. Patients with
maximum grade 2 disease have only a 4.1-month median
survival, and those with grade 3 disease have only a 3.6-
month survival; patients with grade 4 extensive disease have
the worst median survival, at 2.7 months. Overall median
Table 2. Response to ATG Treatment for Steroid-Refractory GVHD, by
Organ*
Organ CR, n (%) PR, n (%) NR, n (%) Pro, n (%)
Skin (n = 56) 19 (34) 14 (25) 18 (32) 5 (9)
Liver (n = 54) 4 (7) 4 (7) 28 (52) 18 (33)
Gut (n = 41) 11 (27) 2 (5) 13 (32) 15 (37)
*NR indicates no response; Pro, progressive deterioration in 1 or
more organ systems without improvement in others.
Table 3. Overall Response to ATG Treatment for Steroid-Refractory
GVHD by Maximum Grade
GVHD CR, PR, MR, NR, Pro,
Maximum Grade n (%) n (%) n (%) n (%) n (%)
Grade 2 (n = 27) 5 6 3 9 4 
Grade 3 (n = 25) 2 4 9 4 6 
Grade 4 (n = 17) 3 1 6 5 2
Grades 2-4 (n = 69) 10 (14) 11 (16) 18 (26) 18 (26) 12 (17)
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survival for all grades was 3.6 months. The Kaplan-Meier
curve of survival by maximum grade is shown in Figure 1.
Despite an initial responsiveness to ATG, there is clearly no
plateau in the survival curve, demonstrating no long-term
response in these patients. Only 3 patients are alive post-
ATG treatment, and 1 has relapsed disease. Cause of death
was relapsed disease in 5% of patients, with the remaining
95% attributed to infection, GVHD, and multiorgan fail-
ure. A subset analysis of the impact of time on steroids prior
to ATG on median survival is illustrated in Figure 2. The
longer time on steroids prior to ATG (>2 months) was asso-
ciated with a better median survival. The median survival of
patients on steroids for <1 month was 1.6 months, on
steroids for 1 to 2 months was 3.6 months, and on steroids
for >2 months was 6 months.
Univariate Analysis of Factors Affecting Overall
Survival
Cox proportional hazards survival analysis was per-
formed to identify factors affecting overall survival. On uni-
variate analysis, patient diagnosis, conditioning regimen,
sex, type of GVHD prophylaxis, type of transplant, and
maximum grade of GVHD did not affect overall survival.
Skin, liver, and gut nonresponsiveness or progression on
ATG did not have an impact on survival in these patients.
However, multiorgan nonresponsiveness and progression
did affect survival significantly (hazard ratio, 1.809; P =
.017), as did total dose of steroids pre– and post–ATG treat-
ment (hazard ratio, 1.344; P < .001). Age had a marginal
effect on survival (hazard ratio, 1.020; P = .039).
Multivariate Analysis of Factors Affecting Overall
Survival
On multivariate analysis, the 2 factors associated with
decreased survival were no response or progression in any
2 organs in a patient receiving ATG and age >35 years.
DISCUSSION
There are several published reports on ATG treatment
of steroid-refractory aGVHD that question ATG’s suitabil-
ity as a standard secondary therapy. Our experience with
ATG as treatment for steroid-refractory aGVHD has been
similarly disappointing. The first report by Gluckman et
al. [7] described 9 patients with severe aGVHD treated
with equine ATG, 15 mg/kg, for at least 5 days. Improve-
ment was observed mainly in patients with skin aGVHD,
and overall survival was poor. There are 3 published stud-
ies from the University of Minnesota [1,2,4]. From the
1990 study, the investigators reported on 197 matched-sib-
ling–donor recipients who had developed ≥grade 2
aGVHD [1]. Sixty-one of the 197 patients developed
steroid-refractory GVHD and received salvage therapy,
including ATG (15 mg/kg twice daily for 5 days)/steroids
(40 mg/m2 per day) in 9 patients. Although, in this study,
the authors did not separate out the responders to salvage
Table 4. Median Survival by Maximum Grade of GVHD
GVHD Maximum Grade Median Survival, mo
Grade 2 4.1
Grade 3 3.6
Grade 4 2.7
Overall 3.6
Figure 1. Kaplan-Meier survival curves of steroid-refractory GVHD
patients treated with ATG therapy. Comparison of patients by maxi-
mum GVHD grade at onset of ATG therapy.
Figure 2. Survival after the onset of ATG salvage therapy. Comparison
of patients having <1 month, 1 to 2 months, and >2 months of steroid
therapy prior to ATG. Median survivals were 1.6 months, 3.6 months,
and 6 months, respectively.
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therapy based on whether they received ATG/steroids ver-
sus methylprednisolone alone, only 7 patients (11%)
achieved a CR. In the second study, published in 1992 [2],
21 unrelated-donor recipients with steroid-refractory
aGVHD were treated with equine ATG, 15 mg/kg IV
twice daily for 8 to 10 doses, along with daily prednisone,
40 mg/m2. Only 4 (19%) of the 21 patients had clinical
improvement demonstrable by day 14 to day 28 after ATG
therapy, and 17 (81%) failed to improve. In the third study,
published in 1997, the Minnesota group [4] reviewed 53
patients receiving ATG salvage therapy and found that
GVHD symptoms were stable or improved in 56% of
patients by day 28. Factors associated with a favorable
response to salvage ATG therapy were identified as skin-
only and less extensive GVHD (clinical stage score, ≤4).
Patients who had multiple-organ involvement, any GI
involvement, or any liver involvement at day 7 and day 28
had poor responses. The analysis did suggest that if a rapid
and sustained response to ATG was achieved, it was pre-
dictive of subsequent better survival at 6 months. In 2001,
Remberger et al. [8] reported on the treatment of 29
patients with severe, steroid-refractory aGVHD with 5 dif-
ferent ATG preparations. The response rate was best in
cases with skin involvement (72%), whereas cases with
liver and gut involvement showed lower response rates
(38%). Survival at 100 days was 37%; however, at 1 year it
was 12%. Most patients died of GVHD, with viral and
fungal infections as contributing causes of death. The
investigators concluded that treatment of severe steroid-
resistant aGVHD added nothing to conventional treat-
ment. Most recently, a 2-institution study by Khoury et al.
[9] reviewed the results of treatment with ATG of 58
patients with steroid-refractory aGVHD and concluded
that initial improvement occurs with ATG treatment in a
minority of patients, primarily patients with skin-only
GVHD, but very few patients become long-term survivors.
Despite initial improvement, 52 patients (90%) died a
median of 40 days after ATG therapy, mainly from pro-
gressive aGVHD and/or infection. The study describes
only 10% of patients having long-term survival (range, 12-
60 months), with the majority being patients with skin-
only GVHD. Couriel et al. [10] have reported best rates of
response to salvage ATG in isolated skin- or GI-involve-
ment–GVHD patients, whereas liver involvement and
poor response at day 28 were highly predictive of mortal-
ity. Using rabbit ATG (thymoglobulin) rather than equine
ATG in treating steroid-refractory aGVHD, McCaul et al.
[11] similarly describe dismal long-term disease-free sur-
vival (6%) despite a significant response rate of 59%. In
this study, the majority of responders died from oppor-
tunistic infections or posttransplantation lymphoprolifera-
tive disorder.
Our data confirm the poor outcome of these studies,
and suggest that the estimated 2-year survival in grades 2-4
moderate-to-severe steroid-refractory aGVHD patients is
on the order of 10%. In addition, our study identiﬁed the
factors that signiﬁcantly affect survival to be progressive dis-
ease or no response to ATG therapy in patients with multi-
organ GVHD involvement and age >35 years. Overall pre-
treatment severity of GVHD, type of GVHD prophylaxis,
and HLA disparity were not major prognostic indicators of
survival outcome for patients receiving secondary therapy in
our study.
Initial response rates to ATG salvage therapy in our
study similarly did not translate into improved overall sur-
vival. Our data conﬁrm that treatment with ATG of steroid-
refractory GVHD is associated with initial improvement of
signs and symptoms, particularly in the skin, but ultimately
long-term responses or survivors are rare. Infection leading
to death was the main complication after treatment with
ATG.
Interestingly, we did a subset analysis of patients in this
study and showed that patients with a longer time (>2
months) on steroids prior to ATG had a better median sur-
vival, although using this criterion may have resulted in
selecting a group with a more favorable prognosis.
Our results conﬁrm the poor survival, despite an initial
improvement, with ATG treatment for steroid-refractory
aGVHD. We believe that ATG should not be considered a
standard salvage therapy. All patients with steroid-refractory
GVHD should be enrolled in clinical studies until there are
data to support a standard salvage therapy. Studies that eval-
uate the potential efﬁcacy of new immunosuppressive agents
as salvage therapy should address response-rate impact on
overall survival.
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